A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Trial end date:
2017-11-06
Target enrollment:
Participant gender:
Summary
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will
evaluate the efficacy and safety of lebrikizumab as monotherapy in the absence of background
IPF therapy and as combination therapy with pirfenidone background therapy in participants
with IPF. Participants will be randomized to receive either lebrikizumab or placebo
subcutaneously every 4 weeks.